Literature DB >> 24802631

Epstein-Barr virus associated peri-implantitis: a split-mouth study.

Fernando Verdugo1, Ana Castillo, Francisca Castillo, Agurne Uribarri.   

Abstract

OBJECTIVES: Herpesviral-bacterial synergism may play a potential role in periodontitis and peri-implantitis (PI) etiopathogenesis. PI lesions can worsen depending on specific microbial challenge and host susceptibility. This cross-sectional split-mouth study aimed to substantiate herpesviral-bacterial co-infection in PI patients and assess associations with periodontopathogen salivary contamination.
METHODS: PCR-based identification was performed on 23 patients presenting PI and contralateral healthy implants, and compared to unstimulated whole saliva. Clinical evaluation included probing depths, bleeding on probing, and suppuration. Radiographs were assessed for the presence of lamina dura and bone loss. Three sample sites per patient were tested: PI lesions, healthy implant sulci, and saliva. Quantitative PCR evaluated Epstein-Barr virus (EBV) and cytomegalovirus (CMV) copy counts. Significance of group comparisons for binary-dependent variables, within-subjects designs, was determined by McNemar's chi-square test. Risk analysis was evaluated through odds ratios (OR).
RESULTS: PI lesions were 14.2 (P = 0.001; 95 % confidence interval [CI], 1.6-124.1) and 3 times (P = 0.03; 95 % CI, 0.7-11.9) more likely to harbor EBV than healthy implants and saliva, respectively. EBV positive predictive value was 90 %. PI was associated with absence of lamina dura and higher periodontopathogen proportions. Saliva sampling showed high agreement with PI bacterial detection (89-100 % rate) but not with EBV (44.4 %). The OR of PI lesions harboring Treponema denticola or Tannerella forsythia was 6.79 (P = 0.007; 95 % CI, 1.8-25.0) and 3.3 (P < 0.0001; 95 % CI, 0.3-34.3) times higher than healthy implants, respectively. Saliva of patients with PI was 5.6 times more likely to be contaminated with Prevotella nigrescens than healthy peri-implant sulci (P = 0.002). PI lesions were 1.92 times more likely to harbor Prevotella nigrescens than healthy implants (P = 0.04).
CONCLUSIONS: EBV is a potential candidate in peri-implantitis etiopathogenesis. Saliva PCR analysis is useful in predicting peri-implantitis-specific bacterial infection but not EBV or CMV. CLINICAL SIGNIFICANCE: Herpesviral-bacterial synergism may favor ongoing microbial challenge in peri-implant disease and exacerbate its progression. EBV infection may explain non-responsive to treatment PI. Peri-implantitis individuals may benefit from antiviral therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24802631     DOI: 10.1007/s00784-014-1250-1

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  36 in total

1.  Mechanical non-surgical treatment of peri-implantitis: a single-blinded randomized longitudinal clinical study. II. Microbiological results.

Authors:  G Rutger Persson; Emelie Samuelsson; Christel Lindahl; Stefan Renvert
Journal:  J Clin Periodontol       Date:  2010-06       Impact factor: 8.728

Review 2.  Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.

Authors:  Martin Savard; Jean Gosselin
Journal:  Virus Res       Date:  2006-03-20       Impact factor: 3.303

3.  Ongoing viral replication is required for gammaherpesvirus 68-induced vascular damage.

Authors:  A J Dal Canto; H W Virgin; S H Speck
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  Modifiable risk factors in periodontitis: at the intersection of aging and disease.

Authors:  Mark A Reynolds
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

5.  Clinical and microbiological determinants of ailing dental implants.

Authors:  Giorgio Tabanella; Hessam Nowzari; Jorgen Slots
Journal:  Clin Implant Dent Relat Res       Date:  2008-04-01       Impact factor: 3.932

Review 6.  Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread?

Authors:  Barbara Adler; Christian Sinzger
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

7.  Human herpesvirus 7, Epstein-Barr virus and human cytomegalovirus in periodontal tissues of periodontally diseased and healthy subjects.

Authors:  Antonella Rotola; Enrico Cassai; Roberto Farina; Elisabetta Caselli; Valentina Gentili; Tiziana Lazzarotto; Leonardo Trombelli
Journal:  J Clin Periodontol       Date:  2008-08-07       Impact factor: 8.728

8.  Herpesviral-bacterial interrelationships in aggressive periodontitis.

Authors:  Işil Saygun; Ayhan Kubar; Atilla Ozdemir; Mehmet Yapar; Jørgen Slots
Journal:  J Periodontal Res       Date:  2004-08       Impact factor: 4.419

Review 9.  Treatment of peri-implantitis: what interventions are effective? A Cochrane systematic review.

Authors:  Marco Esposito; Maria Gabriella Grusovin; Helen V Worthington
Journal:  Eur J Oral Implantol       Date:  2012       Impact factor: 3.123

10.  Higher prevalence of Epstein-Barr virus DNA in deeper periodontal pockets of chronic periodontitis in Japanese patients.

Authors:  Ayako Kato; Kenichi Imai; Kuniyasu Ochiai; Yorimasa Ogata
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

View more
  9 in total

1.  Herpesviral-bacterial co-infection in mandibular third molar pericoronitis.

Authors:  Aleksandar Jakovljevic; Miroslav Andric; Aleksandra Knezevic; Biljana Milicic; Katarina Beljic-Ivanovic; Neda Perunovic; Nadja Nikolic; Jelena Milasin
Journal:  Clin Oral Investig       Date:  2016-09-12       Impact factor: 3.573

2.  Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Authors:  Sara Gianella; Davey M Smith; Eric S Daar; Michael P Dube; Andrea Lisco; Christophe Vanpouille; Leonid Margolis; Richard H Haubrich; Sheldon R Morris
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

3.  Prevalence of Epstein-Barr virus DNA and Porphyromonas gingivalis in Japanese peri-implantitis patients.

Authors:  Ayako Kato; Kenichi Imai; Hiroki Sato; Yorimasa Ogata
Journal:  BMC Oral Health       Date:  2017-12-12       Impact factor: 2.757

4.  Cytokine Levels and Human Herpesviruses in Saliva from Clinical Periodontal Healthy Subjects with Peri-Implantitis: A Case-Control Study.

Authors:  Jaime S Marques Filho; Jorge Gobara; Gustavo Vargas da Silva Salomao; Laura M Sumita; Jamil A Shibli; Renato G Viana; Humberto O Schwartz Filho; Claudio Sergio Pannuti; Paulo Henrique Braz-Silva; Debora Pallos
Journal:  Mediators Inflamm       Date:  2018-08-06       Impact factor: 4.711

Review 5.  Herpesviruses and MicroRNAs: New Pathogenesis Factors in Oral Infection and Disease?

Authors:  Afsar R Naqvi; Jennifer Shango; Alexandra Seal; Deepak Shukla; Salvador Nares
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

Review 6.  The Microbiome of Peri-Implantitis: A Systematic Review and Meta-Analysis.

Authors:  Philipp Sahrmann; Fabienne Gilli; Daniel B Wiedemeier; Thomas Attin; Patrick R Schmidlin; Lamprini Karygianni
Journal:  Microorganisms       Date:  2020-05-01

Review 7.  Epstein-Barr Virus and Peri-Implantitis: A Systematic Review and Meta-Analysis.

Authors:  Elisabet Roca-Millan; Judith Domínguez-Mínger; Mayra Schemel-Suárez; Albert Estrugo-Devesa; Antonio Marí-Roig; José López-López
Journal:  Viruses       Date:  2021-02-05       Impact factor: 5.048

8.  Assessment of Cytokine and Herpesvirus Level in Peri-implantitis and Healthy Patients.

Authors:  Sanjay Kumar Sahoo; Mohammad Jalaluddin; Lipsa Bhuyan; Kailash Chandra Dash; Silpiranjan Mishra; Pallavi Mishra
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

9.  Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma.

Authors:  Leticia Bagan; María-Dolores Ocete-Monchon; Manuel Leopoldo-Rodado; Judith Murillo-Cortes; Jose-M Díaz-Fernández; Rafael Medina-Gonzalez; Concepción Gimeno-Cardona; Jose-V Bagan
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.